



TM

PainChek

Intelligent Pain Assessment


September Quarterly 2025

PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK



Our purpose is to give
a **voice to people**
who **cannot reliably**
verbalise their pain



INVESTOR HIGHLIGHTS

First Mover Advantage	• PainChek offers the world's first and only regulatory-cleared AI-enabled SaaS platform to assess pain and monitor the effect of pain relief in non-communicative populations, administered through a smart phone App
Established and Growing	• Its SaaS Platform is now contracted to +115,000 beds (ANZ, UK and Canada only) across 1,900 care facilities • \$5.6M Contracted Annual Recurring Revenue (ARR) has increased 18% yoy and strong steady state SaaS margins of up to 75% (ANZ, UK and Canada Only) • Net retention rate of ~100% demonstrating long term customer commitment • Over 14 million PainChek assessments have been performed since commercialisation began in 2018
Adult Global Market Opportunity	• The Company is pushing ahead with a major international expansion in a global total addressable market worth US\$4 billion for its flagship PainChek Adult app
Pivotal FDA clearance achieved	• PainChek Adult FDA de Novo cleared on 6 October 2025, opening the US market estimated to be worth \$582 million per annum
Additional Children's Growth Opportunity	• PainChek Infant – recently launched, opening another significant growth opportunity. • Total estimated market size of \$33.6 billion (400m pre-verbal children and 150m born each year to first time parents)

INFLECTION POINTS TARGETED TO BEGIN CY2025

1 US MARKET ENTRY

- **Adult App FDA clearance** – target Q3/Q4 CY2025
- **Establish PainChek Corporation** & core team in USA
- **Complete initial sales** post FDA clearance
- **Expand local strategic partnerships**
- **FDA 510K application** for **Home Care** market




2 CONTINUED GROWTH OF ADULT APP

- **Further penetrate** Aged Care markets (ANZ, UK, Canada)
- **Drive towards operational break even** in ANZ & UK
- Expand further into **Home Care sectors & hospital market**
- Complete **German market validation** work



3 DIRECT TO PARENT MARKET ENTRY OF THE INFANT APP

- **Expand initial market entry** – App Store & Google Play store access **Q2 CY2025**
- **Commercial launch** Q3 CY2025 onwards
- Build **B2C strategic partnerships** for global market penetration



THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION

AI based micro-facial pain expression analysis:

- 3 second scan of patient face
- Recognises 9 micro-facial expressions indicative of pain

Guided digital questionnaire checklist:

- Guides the carer in other pain assessment factors e.g. movement, vocalisation etc.
- Questions with Yes/No decisions


Automated pain assessment score:

- 42 test points
- Generates overall pain severity score
- No pain, mild, moderate or severe and pain profile of the resident


Documented via cloud backend:

- Pain trend line and monitoring of treatment
- Capability to integrate into resident medical records
- Data analytics capability for audit and accreditation

SOFTWARE-AS-A-SERVICE
MEDICAL DEVICE
ENABLES
MOBILE DATA
CAPTURE




115,000 CONTRACTED LICENCES, \$5.6M CONTRACTED ARR & STRONG PIPELINE




- **18% increase** in **contracted ARR** (\$5.6M) and **16% increase** in **actual ARR** (\$3.4M) over the prior year
- **Catholic Healthcare (CHL)** PainChek is now the primary pain assessment tool across CHL residential care and home care services, accounting for 3,750 licenses in Australia
- **Edinburgh Hospital TrakCare pilot with InterSystems** has progressed to Phase 2 wider rollout, after time savings were verified by Pain Nurses
- **New tiered activation agreements** with up to 25% pre-payment in place
- **ARR target of \$5.0m** covers core operating costs in the ANZ & UK business

PAINCHEK QUALIFIED SHORT-TERM PIPELINE EXCEEDS 47,000 NEW LICENCES



CONSISTENT GROWTH IN CLINICAL UTILITY – WORLD'S LARGEST PAIN DATABASE

CUMULATIVE NUMBER OF PAINCHEK ASSESSMENTS



Over **14 million global pain assessments** as of **September 2025** conducted on the PainChek platform across **more than 150,000 residents**



97% increase in global pain assessments over the previous year in Aged Care alone



Strong ongoing growth quarter on quarter in clinical utility & implementation progress




More than 16,000 carers & health care professionals trained

In 12 months PainChek has doubled cumulative assessments to 14 million

PAINCHEK ANALYTICS – PROVIDING CLINICAL INSIGHTS

Through PainChek®'s web portal, care managers can access real time dashboard reporting and data analytics, assisting their team in reducing clinical risk while improving their quality of care.



Pain data trends are graphed to assist caregivers for more **effective pain management, reducing carer burden, risks of falls and hospitalizations***

HealthChek; automatic monthly reports which guide the improvement **clinical outcomes through actionable pain management insights**

Analytics are available via API for those businesses that wish to **integrate reporting directly into their systems**

*See Dovehaven homes UK outcomes data

PAINCHEK ADULT: FDA DE NOVO CLEARED COMMENCING SALES INTO A\$175M ANNUAL LONG TERM CARE MARKET



First to Market Differentiator

First and only medical device cleared to assess pain for dementia residents



Competitive Barriers

Successful 2-year US clinical and AI validation study

US Patent protection until 2038 + copyright



Market expansion

Pursuing 510K applications for Home Care & Hospitals – plus Infant application

FDA clearance accelerates Japan & Brazil regulatory potential

**De Novo is “First-of-a-kind” medical device – establishes a new classification & product code.
Recognition from the FDA that a device is novel & safe/effective for clinical use.**

PAINCHEK IMPLEMENTS FIRST US LONG-TERM CARE CLIENT



Jewish Home Family, a leading senior care organisation in New Jersey, secured as PainChek's first US customer. PainChek has been deployed at its flagship location to enhance pain detection & management for residents living with moderate to severe dementia.

"PainChek's technology aligns with our mission to deliver elder-directed care. It empowers our clinical teams with better insights and supports our residents with more responsive, dignified treatment." Carol Silver Elliott, Jewish Home Family President and CEO



PAINCHEK AT THE AMERICAN HEALTH CARE ASSOCIATION & NATIONAL CENTER FOR ASSISTED LIVING CONVENTION & EXPO IN LAS VEGAS, 20-23 OCTOBER 2025

KEY TAKEAWAYS:

Large client attendance: 3000+ long term care client attendees from across USA

PainChek team: Head of US, Canada & Operations plus new US BDM consultant

Booth & Branding: Dedicated PainChek booth & specific US branding collateral – with FDA De Novo clearance messaging

Outcomes: Strong client engagement & significant lead generation. PainChek on track for rapid sales uptake in US market

Next US PainChek Conference (2–5 November 2025): LeadingAge Annual Meeting, a marquee event for aging services professionals (7,000 attendees & 400+ exhibitors).



PAINCHEK US BROCHURES

Core Brochure: Introduction to PainChek® and its role in transforming pain assessment in long-term care.

PainChek
PainChek®
PainChek®

TRANSFORMING PAIN MANAGEMENT GLOBALLY

PainChek® is an FDA De Novo-granted AI-enabled pain assessment app built on eight years of international clinical use. With over 11 million assessments completed across 1,000+ facilities and 80,000 residents in Australia, New Zealand, UK, and Canada, PainChek® consistently delivers measurable improvements in care quality and safety.

FDA De Novo Pathway: PainChek®'s US clinical validation and FDA De Novo grant.

PainChek
PainChek®
PainChek®

THE SCIENCE BEHIND PAINCHEK®

PainChek®'s AI model is built on the research of Dr. Paul Ekman, a pioneer in studying emotions and their connection to facial expressions. Dr. Ekman's work, which began in the late 1960s, focused on facial muscle movements, known as "Action Units" (AUs).

Ekman's Facial Action Coding System (FACS) is a detailed anatomically based framework used to describe all visible facial movements. PainChek® is the only pain assessment tool to use the FACS coding system to assess facial expressions of pain.

PainChek® is an advanced AI-based facial analysis tool for gait shown to be indicative of pain.

1. Brow lowering
2. Cheek raising
3. Tightening of eyelids
4. Wrinkling of nose
5. Raising of the upper lip
6. Pulling at the corner lip
7. Horizontal mouth stretch
8. Parting lips
9. Closing eyes



Before PainChek®, tools like the Abbey Pain Scale (Abbey et al., 2004) and PAINAD required the user to observe for expressions (e.g., "Some frowning, grimacing, and tightened facial expressions") which could lead to misinterpretation. These expressions reflect average emotional states that do not necessarily correlate with pain, and have facial characteristics inconsistent with pain.

Dr. Jennifer Ashley AM, the creator of the Abbey Pain Scale, is an PainChek® advisory board and consulting, supportive of the shift from the Abbey Pain Scale to PainChek®. Her continued support and involvement highlights the importance of integrating advanced technologies for more accurate pain detection in our industry.

These observations were highlighted in the Handbook of Pain Assessment (Tuck, D. C., & Melnick, R., 2002), which reviewed traditional pain assessment methods.

Science Behind PainChek®: Overview of PainChek®'s AI model and research studies.

PainChek
PainChek®
PainChek®

GIVING A VOICE TO THOSE WHO CANNOT RELIABLY VERBALIZE THEIR PAIN

PainChek® is an FDA De Novo-granted, AI-enabled pain assessment app that brings evidence-based technology directly to the point of care for people living with moderate to severe dementia.



- FDA De Novo granted (DEN149073)
- Validated through a pivotal clinical study in leading US skilled nursing facilities (SNFs)
- Supports compliance with CMS MDS 3.0 requirements, and federal and local pain management guidelines
- Proven over clinical use in Australia, New Zealand, the UK, and Canada since 2017
- Empowers healthcare teams to make informed, personalized care decisions

www.painchek.com

PROVEN GLOBAL OUTCOMES:

- Predictive optimization: Reduced use of analgesics, antidepressants, anxiolytics, and hypnotics
- Resident well-being: Improved nutrition, increased mobility, reduced dependency and improved quality of life
- Safety and care quality: Fewer falls, reduced distress, and improved staff confidence in pain assessment
- Operational benefits: Improved care efficiency and significant cost savings



Global Traction: Proven international outcomes in improving care and reducing risks.

PainChek
PainChek®
PainChek®

A FIRST-OF-ITS-KIND SOLUTION FOR US LONG-TERM CARE

PainChek® has been granted FDA De Novo classification for use in US long-term care skilled nursing facilities, establishing a new FDA product code and making it the first device of its kind authorized for commercial distribution in the United States.

This milestone confirms PainChek® as an innovative, evidence-based solution designed to raise the standard for pain management in long-term care.

THE FDA DE NOVO PATHWAY:

PainChek® received marketing authorization through the FDA De Novo classification process, which established a new device type for digital pain assessment. This authorization confirms that PainChek® met the FDA's requirements for safety and effectiveness for its Intended User Population.

- Backed by Human Factor Validation Testing (HFVT) and a pivotal US clinical study
- Supports compliance with CMS MDS 3.0 requirements, and federal and local pain management guidelines
- Enables consistent, evidence-based care for better resident outcomes

KEY STUDY OUTCOMES

PainChek® demonstrated strong agreement with the internationally recognized Abbey Pain Scale, delivering accurate pain category assessments and superior test-retest reliability. It performed consistently across different resident demographics (age, gender, race, and ethnicity) and device platforms, with statistical validation further confirming its accuracy and clinical strength.

PainChek® & PointClickCare: Integration overview, features and benefits.

PainChek | **PointClickCare**

CREATE SEAMLESS CLINICAL WORKFLOWS WITH THE POINTCLICKCARE® AND PAINCHEK® INTEGRATION



Full brochures available at: <https://www.painchek.com/us/resources/brochures/>

US CLIENTS IMMEDIATE PERCEIVED BENEFITS OF PAINCHEK®

Face Value of the PainChek App

- ✓ **Fits Long Term Care mission – especially valued among mission-driven, faith-based, and non-profit operators where quality of care, not ROI, is the primary goal**
- ✓ A clear understanding of the challenge of assessing pain in cohorts of people who cannot self report
- ✓ **Open to a better way of assessing pain and an appetite for innovative technology - nurses and CNAs expressed low confidence in PAINAD**
- ✓ Helps manage staffing requirements and capability
- ✓ Relative low-cost with high benefit

Long term Care Compliance

- ✓ **Addresses disproportionate violations among cognitively impaired residents, where pain management deficiencies are common**
- ✓ Supports equitable care for residents with cognitive impairment
- ✓ **Helps to deliver better medication management**
- ✓ Drives Value Based Care
- ✓ Optimize cost of care – utilizing mix of nurses and carers
- ✓ Eliminates duplicity of results & provides ROI opportunity
- ✓ Addresses MDS requirements
- ✓ **Integrates directly into EHRs systems (PCC, ElderMark, Yardi) for consistency of clinical data access and storage**

Data Analytics & AI

- ✓ **Higher interrater reliability creates more statistically meaningful pain data**
- ✓ Simple reporting on client results
- ✓ Provides transparency on client pain profiles
- ✓ Review carer interrater performance stats
- ✓ Opportunity to leverage data analytics (PCK opportunity)
- ✓ **An appetite and soft entry point in the adoption of AI for better clinical care outcomes**

Emerging Opportunities

- ✓ **Growing interest in applying PainChek® within Rehab and Therapy domains**
- ✓ Rehab directors (e.g. Jewish Family Home) report conducting pain assessments before and after every session
- ✓ Represents a potential new sub-market and area of expansion identified through recent US engagements

PainChek® is seen to help deliver on several of the long-term care client goals

STRONG GLOBAL TRACTION IN SENIOR CARE FACILITIES WORLDWIDE

PainChek Canada

- 300,000 bed (A\$20M ARR) aged care market
- PCK Adult regulatory cleared & local BDM in place
- ~1,000 beds licensed - established & partners include PointClickCare

Europe* (EU)

- Regulatory cleared & patent secured
- Initial focus 800,000 bed German market – A\$40M ARR
- Application for DiPA reimbursement for German home care market of 4.2M people

PainChek Corp US

- 3,000,000 bed (\$A175M+ ARR) long term care market
- **FDA de Novo regulatory CLEARED**
- Existing PointClickCare & Eldermark & Yardi integration partnerships provides access to 1,300,00 beds (circa A\$60M+ ARR)
- Local US PCK BDM and Ops team in place & pipeline for rapid growth

PainChek UK

- ~43,000 beds licensed to use PCK
- 500,000 bed aged care market
- A\$25M ARR aged care bed market
- 10+ integration partners

Japan*

- 1,100,000 bed (A\$55M ARR) aged care market
- Regulatory clearance process to commence post FDA

PainChek ANZ

- ~71,000 beds licensed to use PCK
- 200,000 bed aged care market
- ~A\$15M annual aged care market
- Home Care & Disabilities markets commenced
- 15+ integration partners

There are over 4.5 million beds within PainChek's initial targeted regions in the long-term care market alone, with a total potential ARR of circa A\$300 million

PAINCHEK® INFANT



A PainChek Limited Product

MAKING INFANT PAIN VISIBLE



MAKING INFANT PAIN VISIBLE

- The newest addition to the PainChek family, **PainChek Infant, is the world's first AI-enabled app for instant pain assessment** on infants aged 1-12 months
- Designed for **in-home use by parents or other non-medical carers**
- Globally, the Infant market **opportunity extends to up to 400 million pre-verbal children and 150 million born to first time parents each year**
- **Regulatory cleared for home use** in multiple markets including **ANZ, EU, UK**. USA regulatory clearance process to be finalised following recent Adult App de Novo clearance



www.painchekinfant.com
www.infantpaincare.com

MAKING INFANT PAIN VISIBLE

PainChek® Infant app is designed with parents and families in mind, offering a comprehensive user-friendly experience with a range of valuable features including:



3-second facial analysis-based pain assessment



Monitoring of historical pain events




Documenting treatments, including medications



Self-guided in-app training




User-friendliness in a non-clinical environment



PAINCHEK CHILDREN'S MARKET STRATEGY – TO ACCESS 400 MILLION PRE-VERBAL CHILDREN WORLDWIDE



PAINCHEK INFANT – INITIAL AUSTRALIA MARKET PERFORMANCE UPDATE



The team continues to monitor performance at each stage of the funnel, with current priorities focused on improving:

- Conversion from download to account registration
- Time from first use to first pain assessment
- Conversion from free trial to paid subscription

PAINCHEK INFANT – MILESTONES AND KEY UPDATES



Complete

Launched Android in the Google Play store

App release 7 October
optimised self registration screens, reduction of free trial from 30 to 14 days

Educator day 16 October with NSW CPR Kids introducing the app to nurses & trainers



In-progress

Clinical review of the app by NSW CPR Kids
& development of pain education material

Website redesign
to improve download CVR & clarity of value

Revised UX in app
to improve CVR



Next

Pricing revision
to shift registration towards annual & lifetime

Execution of social & search campaigns to test messaging
themes & inform future paid media strategy

Ongoing collaboration with key opinion leaders & parent networks
to validate messaging and identify partnership opportunities

LOOKING AHEAD – COMMERCIALISE INFANT TECHNOLOGY GLOBALLY

NOW

SCALING UP FROM Q1 CALENDAR 2026 ONWARDS

Continue to Expand in Australia

- 300k (babies born each year)



Broaden to markets where PainChek has a presence

- UK: 700k
- Canada: 350k



Assess EU market entry opportunities

- CE mark regulatory clearance Germany (690k) & France (660k)



US Market Entry

- FDA follow up to determine regulatory clearance pathway for PainChek Infant App (3.6m)

Build healthcare professional recommendations and consumer advocacy support in each local market to help enable the direct-to-consumer marketing campaigns.



PAINCHEK INFLECTION POINTS ACHIEVED IN CY2025

1 US MARKET ENTRY

- ✓ **Adult App FDA clearance** – target Q3/Q4 CY2025
- ✓ **Establish PainChek Corporation** & core team in USA
- ✓ **Complete initial sales** post FDA clearance
- ✓ **Expand local strategic partnerships**
- ⚙️ **FDA 510K application** for **Home Care** market





2 CONTINUED GROWTH OF ADULT APP

- ✓ **Further penetrate** Aged Care markets (ANZ, UK, Canada)
- ✓ **Drive towards operational break even** in ANZ and UK
- ✓ Expand further into **Home Care sectors and hospital market**
- ⚙️ Complete **German market validation** work



3 DIRECT TO PARENT MARKET ENTRY OF THE INFANT APP

- ✓ **Expand initial market entry** – App Store & Google Play store access **Q2 CY2025**
- ✓ **Commercial launch** Q3 CY2025 onwards
- ✓ Build **B2C strategic partnerships** for global market penetration



BATTLE-TESTED LEADERSHIP & DEEP CLINICAL NETWORK



Philip Daffas

**CEO & Managing Director,
MBA, BSc**

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia



Prof. Jeff Hughes

**Chief Scientific Officer PhD,
MPS**

Jeff is a professor in the School of Pharmacy, Curtin University in Western Australia. Jeff is one of the team who developed the PainChek concept



Andrew Hoggan

Head of Operations

Andy is a Psychologist, management consultant, business leader & executive coach. Andrew has worked in both Australia & the UK across senior care & home care services



Iain McAdam

CFO

Iain has over 20 years finance & transformational change experience within listed high growth multinational software & services companies, including iSoft & eServGlobal



Scott Robertson

**CTO, MBA, B.Eng.
(Comp. Systems)**

Scott has over 25 years' experience designing, deploying & managing enterprise software systems, adapting to changing client needs



Sasha Grant

Head of Infant Growth

Sasha is an experienced business leader in Direct-to-Consumer Apps, product commercialization & online technology having worked with significant global brands including Expedia Group, WikiCamps App (GDAY Group) and EBAY; in Australia and UK.



David Allsopp

**Head of Business
Development, Canada**

David has extensive account management, relationship management. He is renowned for establishing trusting, transparent & long-standing relationships in the healthcare space.



Tandeep Gill

**Senior Business Development
Manager, UK**

Tandeep is a registered pharmacist in hospital & community setting, with 10 years experience in senior health & social care position spending 3 years leading the advancement of technology solutions in the UK.



Christelle Ucinck

**Senior Business Development
Manager, ANZ**

Christelle is a registered pharmacist with over 13 years of healthcare experience, including extensive expertise in pharmacy, senior care, and digital health innovation.



Nick Garofoli

**Head of Business
Development, USA**

Nick has over 15 years of experience in technology leadership; 7 in the senior living industry, including CEO of RCare, Head of US Operations for Nobi and commissioner on Leading Age's CAST technology commission.

THE BOARD



John Murray
Non-Exec Chair

25 years in tech & Venture Capital. Founder of Technology Venture Partners, ex Chair of Residential Aged Care provider. Multiple non-exec board roles.



Philip Daffas
CEO & Managing Director

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia.



Ross Harricks
Non-Exec Director

Senior global medical device executive with Nucleus & experienced healthcare NED.



Adam Davey
Non-Exec Director

Corporate finance executive with extensive capital markets experience.



Cynthia Payne
Non-Exec Director

30 years executive leadership experience as well as significant board and operational experience in residential and home aged care services in Australia.

CORPORATE SUMMARY

Top shareholders %

Peters Investments Proprietary Ltd	6.4%
Founders	3.6%
Board & key staff	4.0%

Financial information

Share price (30 th October 2025)	A\$0.046
Shares on issue	2,091.9m
Market capitalisation	AUD \$96.2M
Cash (30 September 2025)	A\$6.3M
Debt	Nil
Unlisted options/performance rights	463.4m



TM

PainChek

Intelligent Pain Assessment

September Quarterly 2025

PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK